|
ハギワラ シヨウタロウ
萩原 將太郎 所属 医学部 医学科（東京女子医科大学病院） 職種 非常勤講師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | HIV positivity may not have a negative impact on survival in Epstein-Barr virus-positive Hodgkin lymphoma: A Japanese nationwide retrospective survey. |
| 掲載誌名 | 正式名：Oncology letters 略 称：Oncol Lett ISSNコード：(1792-1074)1792-1074(Linking) |
| 掲載区分 | 国外 |
| 巻・号・頁 | 16(3),pp.3923-3928 |
| 著者・共著者 | Yotsumoto Mihoko†, Ito Yoshikazu, Hagiwara Shotaro, Terui Yasuhito, Nagai Hirokazu, Ota Yasunori, Ajisawa Atsushi, Uehira Tomoko, Tanuma Junko, Ohyashiki Kazuma, Okada Seiji |
| 発行年月 | 2018/09 |
| 概要 | There has been no comparative clinical study focused on differences in the clinical features of Epstein-Barr virus (EBV)+ Hodgkin lymphoma (HL) between HIV-positive and -negative cases. In a nationwide survey from 511 institutions in Japan, the present study investigated 16 EBV+ HIVpositive HL patients. To further clarify their characteristics in comparison with EBV+ HIVnegative HL (n=34) in the combination antiretroviral therapy era in Japan, the present study was performed. Results indicated that EBV+ HIVpositive HL frequently occurred in a younger population compared with EBV+ HIVnegative HL (P=0.0295), and that the EBV+ HIVpositive HL group was not associated with the nodular sclerosis subtype in the population who were below the age of 40. Notably, the EBV+ HIVpositive HL group had a significantly higher frequency of extra-nodal involvement (P=0.0214), including marrow invasion. In the advanced stage, 80% of those with EBV+ HIVpositive HL did not require dose-reduction and in the majority of cases, chemotherapy was completed. There were no significant differences in the complete remission rate (P=0.1961), overall survival (P=0.200) and progression-free survival (P=0.245) between EBV+ HIVpositive HL (median observational period, 23.5 months) and EBV+ HIVnegative HL (median observational period, 64.5 months), suggesting that HIV positivity may not have a negative impact on the clinical outcome of EBV+ HL. Notably, standard chemotherapy is effective and tolerable for EBV+ HL, regardless of HIV infection. |
| DOI | 10.3892/ol.2018.9132 |
| PMID | 30128009 |